<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
LONDON–(BUSINESS WIRE)–Citi, acting through Citibank N.A., has been appointed by Molecular Partners AG (“Molecular Partners”), a clinical-stage biotech company, to act as depositary bank for its American Depositary Receipt (“ADR”) programme. Molecular Partners’ American Depositary Shares (“ADS”) trade on the Nasdaq Global Market under the symbol “MOLN”. Each ADS represents one ordinary share of the company. Andreas Emmenegger, Molecular Partners’ CFO, said: “We are pleased to be working with
...read full article on Business Wire
